Search: onr:"swepub:oai:gup.ub.gu.se/297784" >
Realizing Clinical ...
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
-
- Lindegren, Sture, 1960 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiofysik,Institute of Clinical Sciences, Department of Radiation Physics
-
- Albertsson, Per, 1964 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
-
- Bäck, Tom, 1964 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiofysik,Institute of Clinical Sciences, Department of Radiation Physics
-
show more...
-
Jensen, H. (author)
-
- Palm, Stig, 1964 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiofysik,Institute of Clinical Sciences, Department of Radiation Physics
-
- Aneheim, Emma, 1982 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiofysik,Institute of Clinical Sciences, Department of Radiation Physics
-
show less...
-
(creator_code:org_t)
- Mary Ann Liebert Inc, 2020
- 2020
- English.
-
In: Cancer Biotherapy and Radiopharmaceuticals. - : Mary Ann Liebert Inc. - 1084-9785 .- 1557-8852. ; 35:6, s. 425-436
- Related links:
-
https://www.liebertp...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Despite the consensus around the clinical potential of the alpha-emitting radionuclide astatine-211 (At-211), there are only a limited number of research facilities that work with this nuclide. There are three main reasons for this: (1) Scarce availability of the nuclide. Despite a relatively large number of globally existing cyclotrons capable of producing(211)At, few cyclotron facilities produce the nuclide on a regular basis. (2) Lack of a chemical infrastructure, that is, isolation of(211)At from irradiated targets and the subsequent synthesis of an astatinated product. At present, the research groups that work with(211)At depend on custom systems for recovering(211)At from the irradiated targets. Setting up and implementing such custom units require long lead times to provide a proper working system. (3) The chemistry of(211)At. Compared with radiometals there are no well-established and generally accepted synthesis methods for forming sufficiently stable bonds between(211)At and the tumor-specific vector to allow for systemic applications. Herein we present an overview of the infrastructure of producing(211)At radiopharmaceuticals, from target to radiolabeled product including chemical strategies to overcome hurdles for advancement into clinical trials with(211)At.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Keyword
- astatine-211
- targeted alpha
- therapy
- particle-emitting at-211
- in-vivo
- targeted alpha
- n-succinimidyl
- radiopharmaceutical chemistry
- at-211-labeled antibodies
- monoclonal-antibody
- astatination
- reagents
- stability
- Oncology
- Research & Experimental Medicine
- Pharmacology & Pharmacy
- Radiology
- Nuclear Medicine & Medical Imaging
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Lindegren, Sture ...
-
Albertsson, Per, ...
-
Bäck, Tom, 1964
-
Jensen, H.
-
Palm, Stig, 1964
-
Aneheim, Emma, 1 ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
- Articles in the publication
-
Cancer Biotherap ...
- By the university
-
University of Gothenburg